ArticleNeurocritical care2026
Evaluating Utility-Weighted Modified Rankin Scale as an Outcome for Clinical Trials in Subarachnoid Hemorrhage: A SAHaRA Secondary Analysis.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe utility-weighted modified Rankin Scale (UW-mRS) is an emerging alternative to the traditional ordinal mRS as a patient-centered measure of functional outcome in clinical trials. As a quasi-continuous parameter, the UW-mRS has been shown to better represent patient-centered outcomes and enable more efficient power calculations in acute ischemic stroke studies. However, its utility has not yet been tested in patients with subarachnoid hemorrhage (SAH).
methodsIn a secondary analysis of the aneurysmal SubArachnoid Hemorrhage - Red blood cell transfusion And outcome (SAHaRA) randomized clinical trial, the UW-mRS, where higher scores reflect better outcomes, was computed by mapping each mRS category using utility scores reported by the patients, and in addition, using previously published utility weights to validate these weights in this population. The primary and secondary outcomes of SAHaRA were analyzed with the UW-mRS. Power calculations were compared across three possible outcome analytic approaches: binary mRS, ordinal mRS, and UW-mRS.
resultsA total of 725 participants were included. Recalculated utility-weights from SAHaRA closely matched those previously published in ischemic stroke trials. At 12 months, 33.5% of patients in the liberal transfusion arm achieved the predefined unfavorable outcome (mRS ≥ 4) versus 37.7% in the restrictive arm (odds ratio [OR] 0.88, 95% confidence interval [CI] 0.72-1.07, p = 0.24). Using the UW-mRS, the average ± standard deviation in the liberal arm was 0.55 ± 0.39 compared with 0.52 ± 0.39 (linear regression β = 0.04, 95% CI - 0.02-0.09, p = 0.22). Power calculations, assuming 80% power and α = 0.05, indicated that replicating SAHaRA with dichotomized mRS would require 1900 participants per group, 1450 per group with the full-ordinal mRS, and 1460 per group with the UW-mRS. The UW-mRS demonstrated better goodness-of-fit to secondary patient-reported outcomes.
conclusionsThe UW-mRS yielded results consistent with dichotomized mRS while preserving more patient-centered information, improving statistical efficiency, and showing stronger agreement with patient-reported outcomes.
Indexed as
Identifiers
42469581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.